Fatal cardiac arrhythmias are caused by some, but not all, drugs that inhibit the cardiac rapid delayed-rectifier current (IKr) by blocking hERG channels. Here, we propose a novel mechanism that could make certain hERG blockers less proarrhythmic. Several drugs that block hERG channels, yet have favorable cardiac safety profiles, also evoke another effect; they increase the current amplitude upon low-voltage depolarization (facilitation). Voltage-clamp recordings of hERG block and facilitation by nifekalant, a Class III antiarrhythmic agent, constrained a model of human cardiac IKr. In human ventricular action potential simulations, nifekalant showed its therapeutic ability to suppress ectopic excitations, with or without facilitation. Without facilitation, excessive IKr block evoked early afterdepolarizations, which cause lethal arrhythmias. Facilitation prevented early afterdepolarizations at the same degree of block by increasing IKr during repolarization phase of action potentials. Thus, facilitation is proposed to reduce the arrhythmogenic risk of hERG blockers.
Introduction
A rapid component of the delayed-rectifier potassium current (IKr) plays an important role in the repolarization of the cardiac action potential (AP). IKr is especially important in ventricular muscle of the hearts of large mammals. Certain blockers of IKr are class III antiarrhythmic agents, used to treat ventricular tachyarrhythmias (Sanguinetti and Jurkiewicz 1990 , Vaughan Williams 1992 , Clancy et al. 2003 . Blockers of IKr prolong the AP duration (APD) and effective refractory period (ERP) to suppress premature ventricular contraction.
Blockade of IKr also is a side-effect of many drugs. Blockers of IKr can cause acquired long QT syndrome and the life-threatening ventricular tachyarrhythmia called "torsades de pointes" (Surawicz 1989 , Sanguinetti et al. 1995 , Roden 2000 , Sanguinetti and Tristani-Firouzi 2006 , Roden 2008 . Emphasis on detecting IKr blockade early in drug discovery (ICH 2005) has contributed to the successful removal of torsades de pointes risk for new chemical entities.
However, there is concern that promising new drug candidates are being unnecessarily discarded because they benignly block IKr (Sager et al. 2014 , Gintant et al. 2016 . Indeed, numerous examples exist of drugs that block IKr and prolong the QT interval but have little proarrhythmic risk (De Ponti et al. 2001 , Redfern et al. 2003 .
The human ether-a-go-go-related gene (hERG) encodes the ion channel through which
IKr current passes (Sanguinetti et al. 1995) . We have found that some hERG blockers also increase hERG currents at potentials close to the threshold for channel activation. We refer to this electrical phenomenon as 'facilitation' (Hosaka et al. 2007 , Furutani et al. 2011 , Yamakawa et al. 2012 . A series of hERG blockers with lower proarrhythmic risk were found to evoke facilitation of hERG (Hosaka et al. 2007 , Furutani et al. 2011 , Yamakawa et al. 2012 . The correlation between clinical safety and facilitation lead to our current hypothesis: facilitation by hERG blockers increases IKr during cardiac AP repolarization and thereby decreases their proarrhythmic risk. Stringently testing this hypothesis requires a system where facilitation can be selectively removed from a hERG blocker's mechanism. In the present study, we test the aforementioned facilitation hypothesis with a mathematical model of the actions of nifekalant, a hERG channel blocker that induces facilitation and has been used safely in the treatment of lifethreatening ventricular tachyarrhythmias (Nakaya et al. 1993 , Takenaka et al. 2001 , Igawa et al. 2002 , Sato et al. 2017 , on the APs of human ventricular myocytes.
Results

AP voltage stimuli induce facilitation by nifekalant
The degree of facilitation of IKr depends on the dose of hERG blocker and the membrane's history of voltage changes. Facilitation by blockers, with the exception of amiodarone derivative KB130015 (Gessner et al. 2010) , requires a preceding strong depolarization as a conditioning stimulus (Carmeliet 1993 , Jiang et al. 1999 , Hosaka et al. 2007 , Furutani et al. 2011 , Yamakawa et al. 2012 . To test whether cardiac APs are sufficient to stimulate facilitation, we applied an AP clamp protocol to hERG channels. Repeated stimulation with a human ventricular myocyte waveform at 1 Hz induced facilitation of nifekalant-treated hERG channels ( Figure 1 ). The facilitation effect on hERG current saturated as the number of APs increased, indicating facilitation reached 90% of its steady state level within 20 heartbeats ( Figure 1C ). The induction of facilitation by cardiac AP stimuli suggests that facilitation is potentially physiologically relevant.
Facilitation can be incorporated into cardiac electrophysiology modeling
To understand how facilitation could impact cellular electrophysiology mechanisms specific to human ventricular myocytes, we used the O'Hara-Rudy dynamic (ORd) human ventricular AP model (O'Hara et al. 2011) . We modified the IKr formula in the ORd model to reproduce hERG channel block by nifekalant, with or without facilitation. This modified IKr formula was constrained by currents recorded from HEK cells expressing hERG ( Figure 2D , E show experimental hERG currents blocked with 100 nM nifekalant, before (magenta traces) and after the induction of facilitation effect by a conditioning pulse (green traces). After the induction of the facilitation effect, nifekalant enhanced the current induced by a −30 mV pulse ( Figure 2D ), but it still suppressed the current induced by a +30 mV pulse ( Figure 2E ). The current enhancement is due to a modification of channel activation gating that shifts the voltage dependence to more hyperpolarized membrane potentials (Hosaka et al. 2007 , Furutani et al. 2011 . The voltage dependence of the hERG current in the facilitation condition could be described as the sum of two Boltzmann functions reflecting two populations of hERG currents having different activation voltage dependences (Furutani et al. 2011) . The high-V1/2 fraction of the channel population has biophysical characteristics typical for the hERG channel, while the low-V1/2 fraction is 'facilitated'. The facilitated V1/2 was shifted negative by −26.5 mV ( Table 1) . This shift was consistent with that of hERG channels expressed in Xenopus oocytes (Furutani et al. 2011 ). Thus, the facilitation effect could be explained by a fraction of channels opening with a negatively shifted activation curve ( Figure 2F, G) . Inclusion of the facilitation effect in the IKr model reproduced measurements of hERG currents from voltage-step experiments ( Figure 2D -G) , and over a range of concentrations (Supplemental Figure 2) . In AP clamp experiments and simulations, our IKr model also predicted the effects of nifekalant on hERG currents during AP ( Figure 2H) , indicating that the model describes the block and facilitation effects of nifekalant sufficiently to allow us to assess the impact of facilitation in simulations of human ventricular myocyte electrophysiology.
Facilitation selectively increases IKr during late phase-2 and phase-3 repolarization of cardiac APs
To understand the role of facilitation in the cardiac AP, we investigated the influence of facilitation on AP morphology. When endocardial APs are evoked with 1 Hz pacing, 100 nM nifekalant prolonged the APD measured at 90% repolarization, APD90, (334.4 ms, vs. 257.4 ms in the control condition, see Figure 3A ), in agreement with experimental results in human ventricular myocytes (Jost et al. 2005) . The AP was slightly further prolonged in simulations with IKr block without facilitation (342.0 ms APD90, compare green and magenta traces in Figure   3A ). In the model, 100 nM nifekalant blocks 40% of total IKr at voltages > 0 mV with or without facilitation ( Figure 2G ). When facilitation is implemented in the model, 32% of the hERG channels enter a facilitated state such that they produce substantially more IKr than control conditions when the potential is between −20 and −50 mV ( Figure 2G ). There was little difference between the voltage-dependent activation variables in the IKr model during phase-1 and phase-2 of the AP (xr1 and xr2 for the unfacilitated channels and facilitated channels, respectively), indicating IKr behaved similarly ( Figure 3B, C) . During late phase-2 and phase-3 repolarization, an increase can be seen in IKr (asterisks in Figure 3A -C). However, in block conditions with or without facilitation, the APs were terminated by increase in the inwardrectifier potassium current (IK1)-mediated repolarization current ( Figure 3D ) after a short time, before much prolongation of the AP by facilitation. Thus, in this model of a healthy heart under unstressed conditions, facilitation by this hERG blocker selectively increases IKr during late phase-2 and phase-3 repolarization, but this has only a subtle effect on the cardiac AP.
Facilitation relieves reverse frequency-dependence of APD prolongation
Class III arrhythmic agents are hERG blockers that are used clinically to suppress ventricular tachyarrhythmias (Sanguinetti and Jurkiewicz 1990 , Vaughan Williams 1992 , Sanguinetti and Tristani-Firouzi 2006 . To suppress tachyarrhythmias without provoking torsades de pointes, IKr block would ideally be use-dependent and prolong APD only in response to high frequency stimulation (Surawicz 1989, Hondeghem and Snyders 1990) . Previous studies reported that actions of sotalol (Hafner et al. 1988, Hondeghem and Snyders 1990) and dofetilide (Tande et al. 1990 ), trend against this antiarrhythmic ideal by prolonging APDs more at low than high frequencies, showing reverse frequency-dependence. Notably, sotalol and dofetilide are hERG blockers that do not induce facilitation (Furutani et al. 2011 , Yamakawa et al. 2012 .
Nifekalant also showed reverse frequency-dependence, but it was not as marked (Nakaya et al. 1993 , Cheng et al. 1996 , Igawa et al. 2002 . To determine why, we used our model to test the frequency-dependent effects of nifekalant on APD. The left panel of Supplemental Figure 3 shows changes in the APD90 with 100 nM nifekalant at stimulation frequencies from 0.2 to 2 Hz.
Without facilitation (magenta trace in Supplemental Figure 3 , left), the prolongation of APD was more effective at lower stimulation frequencies, resulting in a reverse frequency-dependence.
When facilitation was included in the model, the reverse frequency-dependence became slightly weaker at low frequencies (green trace in Supplemental Figure 3 , left). APD90 with facilitation was 5.5 ms shorter than without at 2.0 Hz, 7.7 ms shorter at 1.0 Hz, and 10.7 ms shorter at 0.2 Hz (Supplemental Figure 3, right) . This suggests facilitation can partially relieve the reverse frequency-dependence that is a risk factor for torsades de pointes.
IKr facilitation has greater impacts on repolarization in a failing heart model
Heart failure patients are at risk for malignant ventricular arrhythmias. Clinical and theoretical data has shown that the APs in heart failure patients at slow and modest heart rates are destabilized compared with healthy subjects (Bayer et al. 2010) . A more recent study indicated the APs of the heart failure models exhibit stronger rate-dependence when compared with the APs of the normal model, and can generate early afterdepolarizations (EADs) and alternans at modest pacing rates (Elshrif et al. 2015) . These features are thought to trigger ventricular arrhythmias (Roden 2000 , Thomsen et al. 2003 , Nattel et al. 2007 , Roden 2008 , Weiss et al. 2010 . To determine whether facilitation might have a more critical impact on failing hearts, we investigated the frequency-dependent effects of IKr facilitation on the simulated AP in a heart failure model (Figure 4) (Elshrif et al. 2015) . APs in the heart failure model were prolonged from the control (non-heart failure) model (compare black traces in Figure 4B , Supplemental 
IKr facilitation prevents EAD
Excessive AP prolongation by a hERG blocker showing strong reverse frequency-dependence creates an electrophysiological environment that favors the development of EAD at low stimulating frequencies. Increasing IKr block from 40% to 50% caused further APD prolongation ( Figure 4C, D) . Without facilitation, the APD was dramatically prolonged with low frequency pacing (magenta trace in Figure 4C ). We found that in the heart failure model paced at 0.2 Hz, EAD appeared at 50% IKr block without facilitation (magenta traces in Figure   4D ), and facilitation suppressed these EADs (green traces in Figure 4D ). Although this pacing is unphysiologically slow, these findings suggest hERG facilitation could have a more significant impact on arrhythmogenesis in a failing heart.
To determine the range of conditions over which facilitation could potentially suppress proarrythmic effects of hERG blockade, we extended analysis in the heart failure model. Figure   5D shows the changes in APD90 as a function of the degree of IKr block. Below 40% block, the drug prolonged APD90 similarly with or without facilitation ( Figure 5A, D) . Without facilitation, APs were destabilized when IKr inhibition was > 48% (section sign in Figure 5D ; APD90 = 890.0 ms), resulting in an alternating EADs and periodic EADs. With facilitation, EADs did not appear until 57% inhibition of IKr (pipes in Figure 5D ; APD90 = 896.4 ms), indicating that IKr facilitation stabilized the AP. Figure 5B , C show examples of steady-state AP trains with 50% and 55% block of IKr (conditions indicated by dagger and double-dagger in Figure 5D , bottom), respectively. These results suggest the facilitation of IKr by blockers reduces proarrhythmic side effects by preventing the development of EADs. In the non-failing heart model, a similar antiarrhythmic effect of facilitation was observed with more extreme IKr blockade (Supplemental Figure 4) .
IKr facilitation suppresses reactivation of L-type Ca 2+ channels. In the heart failure model at 55% inhibition of IKr without facilitation (magenta lines in Figure 6 , left), the repolarization delay caused by IKr reduction augmented the window current in L-type Ca Then, the stagnated repolarization caused more reactivation of L-type Ca 2+ channels (arrowhead in Figure 6C , left), enhancing an inward current component of the net ionic current (Inet) during late AP phase-2 ( Figure 6D , left). This caused the inward-outward balance of Inet (asterisks in Figure 6D , left) that temporally interrupted AP repolarization, followed by a second rising phase of the AP that led to EAD. This IKr block-induced dysfunction eventually converged to a periodic EAD response ( Figure 5C and Figure 6A , right column). In contrast, an increase in IKr due to facilitation ( Figure 6E , right) enhanced an outward current component in Inet during late AP phase-2 and phase-3 ( Figure 6D , right). This accelerated the membrane repolarization and completed the AP repolarization ( Figure 6B , right). Thus, facilitation suppresses EADs by selectively amplifying IKr during late phase-2 and phase-3 of APs when the repolarization is in danger of stagnating. The facilitated IKr overwhelms the reactivating ICaL, preventing EAD.
Modeling suggests IKr facilitation could improve patient safety
Class III antiarrhythmic agents are powerful antiarrhythmics used to treat patients with serious ventricular tachycardias in spite of their narrow therapeutic index (Tamargo et al. 2015) .
The maximal therapeutic dose of Class III antiarrhythmics is generally limited by proarrhythmic risk of IKr block. At low doses with minimal proarrhythmic risk, nifekalant suppresses malignant ventricular tachyarrhythmia (Takenaka et al. 2001 ) and improves short-term and longterm survival of adult patients with ventricular fibrillation/pulseless ventricular tachycardia (Sato et al. 2017) . In animal models, a torsades de pointes response was not detected with the therapeutic dose of nifekalant (Satoh et al. 2004) , and nifekalant has a broader safety window than IKr blockers without facilitation (Sugiyama 2008 , Yamakawa et al. 2012 . To determine whether nifekalant's favorable safety profile could be related to the facilitation mechanism, we conducted simulations of nifekalant's predicted safety window with and without facilitation.
We calculated the "therapeutic" dose of nifekalant that prolongs APD90 by 500 ms, an established clinical standard (Igawa et al. 2002 , Drew et al. 2010 . With facilitation, the simulated therapeutic dose was 278.9 nM (68.0% IKr block); without facilitation, 14% less drug was required, 240.2 nM (64.1% IKr block) ( Figure 7 ). To confirm the antiarrhythmic effect of nifekalant at those therapeutic doses, we assessed the vulnerability of cardiomyocytes to premature excitation. We measured the refractory period of APs in the normal, non-failing model by calculating the shortest timing sufficient to produce secondary voltage overshoot by a second stimuli (S2 stimuli) after regular pacing (S1-S2 stimulation protocol). The effective refractory periods with nifekalant were 216 ms or 215 ms longer than control, with or without facilitation, respectively (Supplemental Figure 5) , suggesting that facilitation has little impact on effectiveness as a Class III antiarrhythmic. We simulated the safety window for nifekalant as the ratio of the dose that produces toxicity (EAD) to the therapeutic dose. Without facilitation, EADs occurred at 657.5 nM, 2.74× the calculated therapeutic dose (Figure 7 ). With facilitation, EADs did not occur until 894.5 nM, 3.21× the therapeutic dose. Thus facilitation widens the simulated safety window for EADs, suggesting that with facilitation an IKr blocker can remain an efficacious class III antiarrhythmic agent, with an improved safety profile.
Discussion
The objective of this study was to examine the influence of the facilitation mechanism on electrical activity in cardiomyocytes. This mathematical model represents a general view of the role that facilitation may play with IKr blockers. We found that IKr facilitation effects on simulated cardiac APs depended on the AP morphology and APD. Facilitation enhances IKr during prolonged APs. The repolarizing effect of facilitated IKr is augmented at low frequencies and as APD prolongs, thus avoiding repolarization reserve impairment, and suppressing EAD development. Therefore, hERG channel blockers with facilitation may offer a safety advantage for arrhythmia treatment.
Our conclusions are based on modeling, yet suggest a general cardioprotective mechanism. To exert cardioprotective effects in vivo, certain conditions are required. First, the concentration of the agent needs to reach the effective concentration for facilitation.
Second, the membrane potential must induce the IKr facilitation effect. We have previously reported the concentration-and voltage-dependence relationships between block and facilitation for several drugs in hERG channels expressed in Xenopus oocytes (Furutani et al. 2011 , Yamakawa et al. 2012 . In the present study, we evaluated the concentration-dependence of nifekalant on hERG channels expressed in HEK293 cells. As in oocytes, the IC50/EC50 for block and facilitation by nifekalant were similar (92.84 ± 7.71 nM for facilitation; 144.92 ± 16.00 nM for block, see Table 1 ). However, for other class III antiarrhythmic agents, the concentration-dependences of block and facilitation are distinct. For example, the EC50 for IKr facilitation by amiodarone is lower than that for IC50 block (Furutani et al. 2011) . These data indicate that when these agents are administrated in the treatment of arrhythmias concentrations effective for block, they certainly also reach the effective concentration for facilitation. Our experimental data showed that facilitation by nifekalant could be induced by cardiac APs ( Figure   1 ). An important finding of this work is that facilitation had a negligible impact on APs under normal conditions (Figure 3) , suggesting that facilitation would not greatly affect normal ECGs.
Our simulation study suggests that facilitation may have a selective impact during severe repolarization impairment and heart failure conditions, leading to a lower risk of arrhythmias.
It is widely accepted that IKr plays an important role in the repolarization of the AP (Surawicz 1989 , Sanguinetti and Jurkiewicz 1990 , Clancy et al. 2003 , Sanguinetti and Tristani-Firouzi 2006 . The decrease in IKr is believed to be associated with EADs, an important cause of lethal ventricular arrhythmias in LQT syndrome and heart failure.
Experiments from Guo et al (Guo et al. 2011) , in isolated non-failing human endocardial ventricular myocytes, showed EADs in the presence of the IKr blocker dofetilide (0.1 µM, corresponding to ~85% IKr block (Thomsen et al. 2003) ), which induces torsades de pointes arrhythmias (Thomsen et al. 2003) . In the present study using the modified ORd model, we successfully reproduced the experimental results of Guo et al (Guo et al. 2011) , as did the original ORd model (O'Hara et al. 2011 ).
Reverse-frequency dependent action on APs is a property common to Class III antiarrhythmic agents (Hafner et al. 1988 , Hondeghem and Snyders 1990 , Tande et al. 1990 , Carmeliet 1993 , Jurkiewicz and Sanguinetti 1993 , Nakaya et al. 1993 , Jiang et al. 1999 , and the associated proarrhythmic risk limits their clinical usefulness (Hondeghem and Snyders 1990, Okada et al. 1996) . Reverse-frequency dependence of IKr block was first explained by an increase in the slowly activated delayed-rectifier K + current with rapid heart rates (Jurkiewicz and Sanguinetti 1993) . Drug mechanisms can prolong APD at higher stimulation frequencies to attenuate reverse-frequency dependence (Hondeghem and Snyders 1990) . For example, some IKr blockers, such as vesnarinone, have high affinities to opened and/or inactivated hERG channels and exhibit an accumulation of inhibition at higher stimulation frequencies (usedependent block), reducing proarrhythmic risk (Toyama et al. 1997 ). In our model, IKr block is not altered by stimulation frequency. Therefore, the reverse-frequency dependence may be even less than predicted. Facilitation attenuates reverse-frequency dependence by enhancing IKr during late phase-2 and phase-3. The effect on reverse-frequency dependence becomes more prominent at higher concentrations of drug. Figure 4A and Supplemental Figure 3 shows the effects of the modest IKr block by 100 nM nifekalant (~40% IKr block and ~32% IKr facilitation).
When the drug concentration increased, the effect of facilitation was more prominent ( Figure   4B ) because of the concentration-dependent increase in the facilitated fraction and the prolonged phase 2-3 of AP. Under the higher concentrations of blocker, EADs and alternans emerged at low frequencies that dramatically affect APD ( Figure 4B ). These EADs were effectively suppressed by IKr facilitation ( Figure 5 , 6, Supplemental Figure 4 ).
Previous studies showed that ICaL reactivation is crucial for the development of EADs , O'Hara et al. 2011 , Tsumoto et al. 2017 . These limitations notwithstanding, this study sheds light on the potential impact of facilitation on cardiac safety, defining a novel mechanism that could suppress proarrhythmic risk and broaden the safety window of hERG blocking agents. The facilitation effect may explain the reason many clinically useful drugs, especially Class III antiarrhythmic agents, are surprisingly safe, despite hERG block and QT interval prolongation. Meanwhile, a lack of a facilitation effect may explain why dofetilide, d-sotalol, atenolol, and terfenadine have a high risk for lethal arrhythmia (Furutani et al. 2011 , Yamakawa et al. 2012 ). Recent studies have described the general utility of the in silico integration of drug effects on multiple cardiac currents to reduce false-positive and false-negative classifications based on hERG block alone (Mirams et al. 2011 , Kramer et al. 2013 . More elaborate models incorporating detailed descriptions of ion channel modulation will improve future investigations on the clinical significance of Class III antiarrhythmic agents.
In conclusion, hERG blockers with facilitation effects may have a lower risk for inducing
EADs and other triggered activities and thus be more suitable to treat arrhythmias. This finding has the potential to improve the early assessment of cardiotoxicity risk using in vitro ion channel assays, thereby reducing the likelihood of mistakenly discarding viable drug candidates and speeding the progression of safer drugs into clinical trials and clinical use.
Materials and Methods
Cell preparation and hERG channel current recording
A human embryonic kidney (HEK) 293 cell line stably-expressing hERG was kindly provided by Dr. Craig T. January (Zhou et al. 1998) . Cells used for electrophysiological study were cultured on coverslips in 12-well plates and transferred to a small recording chamber mounted on the stage of an inverted microscope (Axiovert S100, Carl Zeiss, Oberkochen, Germany), and were superfused with HEPES-buffered Tyrode solution containing (in mM) 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES (pH 7.4 with NaOH). Membrane currents were recorded in a whole-cell configuration using suction pipettes (Hamill et al. 1981) . Leak . In a few experiments, data were initially obtained with HEK293 cell and Xenopus laevis oocyte at room temperature as described previously (Hosaka et al. 2007 , Furutani et al. 2011 . Frogs (Xenopus laevis) were treated under the guidelines for laboratory animals of Osaka University
Graduate School of Medicine.
Nifekalant was obtained from Nihon Schering (Osaka, Japan) and Cayman Chemical (Ann Arbor, MI).
MiRP1 (KCNE2) is a b-subunit of IKr (Abbott et al. 1999) . We examined whether nifekalant caused distinct effects on currents mediated by hERG alone and by hERG and KCNE2. In these experiments, we co-expressed KCNE2 in hERG-expressing HEK293 cells by using pcDNA3 plasmid vector. However, the drugs caused virtually identical effects on the two channels currents in the dose-response (data not shown) and shift of the activation curve (Table   1) . Therefore, we utilized HEK cells and oocytes expressing hERG channels alone for further experiments.
Formulations of kinetic properties for hERG current
To model the macroscopic current of hERG channels expressed in HEK293 cells, we first estimated the kinetics of the channels. The voltage-dependent activation kinetics (time constant of activation) was determined from current activation experiments (Figure 2A) . The activation time constant was measured by fitting IKr activation at each depolarized voltage pulse, Vdepo, (typically Vdepo greater than −40 mV) with a single exponential function:
where K is the asymptote and txr(Vdepo) is the activation time constant. Figure 2A and
Supplemental Figure 1A shows the activation time constants as a function of Vdepo.
Furthermore, the voltage-dependent deactivation kinetics was divided into two processes (i.e., fast and slow processes) in accordance with the O'Hara-Rudy formalism (O'Hara et al. 2011) . Figure 1B) , the deactivation time constants were measured by fitting IKr deactivation at each repolarized voltage pulse, Vrepo, (typically Vrepo less than −30 mV) to a double exponential function:
From current deactivation experiments (Supplemental
Ideact(t) = K+A1·exp(−t/txr,fast(Vrepo))+A2·exp(−t/txr,slow(Vrepo)),
where K is the asymptote, and A1 and A2 are the relative components of the fast and slow processes, txr,fast and txr,slow are the fast and slow deactivation time constants, respectively.
Supplemental Figure 1B , C show the fast and slow deactivation time constants as a function of Vrepo, respectively. Each time constant value in Eqs. 1 and 2 was determined by nonlinear leastsquares fitting. From these experimental data, the activation and deactivation time constants were expressed as continuous functions of membrane potential, Vm, as follows (Supplemental Figure 1E , F):
For txr,slow, if Vm ≥ −80 mV (4) and Vm < −80 mV,
Modeling of IKr
The IKr current was defined as
where GKr is IKr conductance (mS/cm 2 ) under the drug action, Vm is the membrane potential (mV), EK is the reversal potential, Op is the open state variable in the activation of IKr channel and RKr is a time-independent function related to the inactivation property for IKr, respectively.
The voltage-dependence of the Op in Eq. 6 was defined as
where xr1 and xr2 are voltage-dependent activation variables for unfacilitated and facilitated components in the IKr, respectively, and f is a fraction of unfacilitated component in IKr current.
The does-fraction relationship of f for nifekalant with an EC50 of 92.84 nM and a Hill coefficient (he) of 1.50 was represented as follows: . (10) The unfacilitated (xr1) and facilitated activation (xr2) variables were calculated with the following first-order differential equation:
where xri,∞, for i = 1, 2, is the steady-state value of xri,j, i.e., the voltage-dependent activation curve in the hERG channel, and txr,j for j = fast, slow, is the time constant for xri,j, and F is a 
where [D] is the drug concentration (µM) and gKr is the IKr channel conductance absent drug.
The gKr was set to 0.058 mS/cm 2 to recapitulate the APD represented in the ORd model (O'Hara et al. 2011 ).
In addition, we constructed a conventional block model modified only in IKr conductance (block without facilitation model) for comparison with the block model with facilitation. contractions, additional simulations were performed using the S1-S2 stimulation protocol: S1 stimuli until the AP converged to a steady-state were applied at the stimulating frequency of 1 Hz followed by an S2 stimulus with various coupling intervals. When the arrhythmogenicity of the hERG channel blocker was examined, the stimulating frequency was set to 0.5 Hz to avoid the stimulus being applied prior to the complete repolarization of the AP. All simulations were encoded in C/C++, and run on an IBM-compatible computer with the Intel ICC compiler version 15.0.1.
Simulation protocol and computation
Voltage-clamping simulations for calculating
Data and materials availability
These modified ORd models (non-heart failure and heart failure models) that constructed in the present study were also implemented in an XML-based Physiological Hierarchy Markup Language (PHML), which is available at http://physiolodesigner.org/ as an open-access resource.
Details on the modified ORd models as non-heart failing (and failing) endocardial myocytes with and without facilitation effect can referred from PHML models in PH database 
